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BY-NC-ND license (http://creativecomAbstract Background/Purpose: Colonization, infection, and clonal dissemination of
vancomycin-resistant enterococcus (VRE) have been reported in the literature. We aimed to
investigate the incidence rate of VRE acquisition and route of transmission of VRE within the
medical intensive care unit (ICU) to prove whether subclinical transmission occurs in medical
ICUs.
Methods: Between March 1, 2012 and September 30, 2013, rectal cultures were obtained from
all inpatients on admission and after admission to medical ICU. Strain types of VRE were deter-
mined by both multilocus sequence typing and pulsed-field gel electrophoresis.
Results: A total of 66 of the 405 rectal swab surveillance cultures obtained from 46 inpa-
tients were positive for VRE, among which 27 inpatients were culture-positive for VRE on
admission to medical ICU, and 19 inpatients were initially culture-negative but converted
to culture-positive after admission. All isolates carried vanA gene consisting of 51 Entero-
coccus gallinarum, 13 Enterococcus faecium, and two Eenterococcus casseliflavus. Of the
51 E. gallinarum isolates, 40 were type ST 341, seven were ST 252, two were ST 78, and
two were ST 64. The Enterococcus spp., MLST and PFGE subtypes were almost similar among
these two groups of inpatients. Linezolid and tigecycline were most active against VRE
in vitro.nfectious Diseases, Chang Gung Memorial Hospital, 222, Mai Chin Road, Keelung, Taiwan.
t.net (S.-C. Lee).
.11.002
ociety of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC
mons.org/licenses/by-nc-nd/4.0/).
750 S.-C. Lee et al.Conclusion: Subclinical VRE cross transmission may occur in ICU. Active surveillance and
maximal barrier precautions of VRE are required at ICU with high colonization rate of VRE
and shall be beneficial.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Background
Vancomycin-resistant enterococci (VRE) colonization and
infection have been reported worldwide, particularly
among hemodialysis patients and intensive care unit (ICU)
patients1e5, causing unexpected hospital outbreaks.6e11 As
nosocomial infections due to VRE are usually preceded by
colonization and is an international problem, it is necessary
to investigate, especially amongst the ICU patients, VRE
colonization rate, sequence types, and the route of trans-
mission to prove whether subclinical transmission occurs in
ICU.6e12 Effective measures to control VRE in ICU such as
maximal barrier precautions can therefore be established.8
We performed an active surveillance culture with rectal
swabs for every inpatient on admission and after admission
to our ICU during the 1 year and 8 months period. Envi-
ronmental culture for VRE in the ICU was also performed.
All VRE isolates from the ICU inpatients and environment
were studied with molecular typing to investigate the
epidemiology and route of transmission of VRE in the ICU.
Genotypes and antibiotic susceptibility of the VRE isolates
were also conducted.
Methods
Setting and study design
Chang Gung Memorial Hospital at Keelung in Taiwan is a
1088-bed tertiary-care teaching hospital with w50,000 ad-
missions per year. Between March 1, 2012 and September 30,
2013, we carried out a surveillance study of VRE amongst
patients upon admission to medical ICU (MICU) which cared
for both critical cardiac and respiratory failure patients with
20 beds and w500 admissions per year. All strains of VRE
isolated from surveillance rectal culture from MICU patients
were collected and stored for further epidemiological and
antibiotics susceptibility study. Clinical isolates of VRE
causing symptomatic infections in ICU during this period
were also collected and stored for further epidemiological
study. This study was performed after the research plan was
approved by the Committee of Medical Research and the
Committee of Human Trials and Medical Ethics of our hos-
pital Chang Gung Memorial Hospital, Keelung
(CMRPG2B0261-2 and IRB 100-3609B). Written informed
consents were obtained from all participants in the study.
Surveillance rectal swab cultures for VRE from
patients of medical ICU
Critical patients in all rooms of the medical ICU from March
1, 2012 and September 30, 2013 excluding those with acutemyocardial ischemia, acute myocardial infarctions in whom
rectal swabs were contraindicated and those unwilling to
accept rectal swab culture were included in this study.
Screening with baseline rectal surveillance cultures for VRE
were performed within 72 hours of admission to medical
ICU after receiving patients’ consent and repeated
screening at 5e7-day intervals until transfer to general
wards or expiry in ICU. All rectal swabs were inoculated on
to blood agar for further analysis of VRE.13
Infection control policy
All rooms in our medical ICU were single patient rooms with
routine cleaning. Every nurse cared for only two patients in
two single rooms in medical ICU. Once VRE was isolated
from any ICU patient, the head nurse of ICU was notified
and barrier precautions including gloves and gowns were
performed appropriately. Routine environmental cleaning
of these rooms were also intensified.8e11
Surveillance culture of environment for VRE to
detect contamination
Cultures for VRE were also performed from the environ-
ment, including bedrails, ventilator monitor surface,
ventilator tubing, electrocardiogram (EKG) monitor sur-
face, emergency button, inside room desk surface, and
interroom nurse desk surface for onethird of the rooms
rotating every 2e3 months at the medical ICU to detect VRE
contamination.
Analysis of VRE
All rectal swabs were inoculated onto blood agar. Plates
were examined after 48 hours of incubation at 36C. Col-
onies were identified as Enterococcus spp. by matching
with the characteristics of enterococcus, such as Gram-
positive cocci, no inhibition by optochin, changing bile-
esculin to black color, and growth in 6.5% NaCl. Entero-
coccus spp. were classified to specific species by differen-
tial utilization of arginine, sorbitol, arabinose, raffinose,
and the rapid 32 Strep kit test (BioMerieux Vitek Inc.,
Hazelwood, MO, USA). Vancomycin-resistant enterococcus
were confirmed by growth in brain heart infusion agar
containing 6 ug/mL vancomycin.13e16 Antibiotic suscepti-
bility was tested by Etest methods.17
Genotype analysis
Isolates of VRE were typed with multilocus sequence typing
(MLST) using seven primers followed by gene sequence
Table 1 Basic data of VRE surveillance cultures isolates, molecular types and antibiotic susceptibility from patients on and after admission to MICU excluding six duplicate
isolates.a
Total SC /
patients
No./þ SC/þ
patients No.
VRE spp. (n) vanA
gene
MLST
type (N )
PFGE(N ) MIC ug/mL (mean/range/susceptibility %)
Van Teic Fusi Mup Line TSb Tige Dapt
405/248/60/
46
Enterococcus
gallinarum
(45)
(þ) 341(34) A4(10) > 256 316.4/12e>256 1.98/0.25e3 0.43/0.19e1 0.65/0.19e1.5 > 32 0.63/
0.125e0.94
4.12/0.38
e24
A3(10) > 256 322.8/12e>
256
2.09/0.125e3 0.43/0.125
e0.75
0.93/<0.016
e2
57.6/
0.032e> 32
0.33/
0.064e0.94
2.23/0.75e3
B1(3) > 256 > 256 2.67/2e3 0.58/0.5e0.75 0.83/0.75e1 > 32 0.47 2.31/0.94e3
C3(5) > 256 208.8/6e>256 1/0.25e3 0.55/0.5e0.75 1.8/1e3 > 32 0.48/0.094
e2
3.6/2e6
C1(1) > 256 8 2 0.38 2 > 32 0.064 3
D1(5) > 256 7.2/6e12 0.5/0.25e0.75 0.48/0.38e0.5 2.1/1.5e3 > 32 0.11/
0.094e0.125
3.8/3e4
252(7) A1(2) > 256 268/24e> 256 1.69/0.38e3 0.63/0.5e0.75 1.75/1.5e2 > 32 0.5/
0.064e0.94
3.5/3e4
A2(1) > 256 16 3 0.38 2 > 32 0.064 0.25
A3(1) > 256 > 256 2 32 1 > 32 0.64 4
D1(1) > 256 32 0.38 0.75 3 > 32 0.064 3
D2(1) > 256 8 0.75 0.5 1.5 > 32 0.125 4
D3(1) > 256 32 3 0.5 1.5 > 32 0.094 3
78(2) A4(2) > 256 > 256 3 0.69/0.38e1 256.5/1e>
256
> 32 0.94 1.47/0.94e2
64(2) A3(1) > 256 > 256 0.25 0.75 0.75 > 32 6 2
D1(1) > 256 24 0.5 0.5 1.5 0.047 0.064 2
ALL > 256/
> 256/0
249.2/6e
>256/20
1.73/
0.125e3/37.8
1.2/
0.125e32/
97.8
12.6/<0.016e>
256/97.8
61.2/0.032e
>32/4.44
0.51/
0.064e6/
97.8
3.08/
0.13e24/
93.3
Enterococcus
faecium
(13)
(þ) 341(10) A1(1) > 256 24 3 0.5 2 > 32 0.094 2
A4(1) > 256 12 1.5 0.125 0.19 12 0.125 0.38
B1(1) > 256 > 256 3 0.5 0.75 > 32 0.47 3
C3(2) > 256 19/6e32 0.44/0.38e0.5 0.44/0.38e0.5 1.75/1.5e2 32.02/
0.032e>32
0.16/
0.064e0.25
3
C2(1) > 256 16 2 0.38 1.5 0.094 0.064 3
D1(4) > 256 8.5/6e12 0.85/0.38e2 0.44/0.38e0.5 1.88/1.5e2 > 32 0.12/
0.094e0.125
4.5/4e6
252(2) A4(1) > 256 32 0.38 0.5 3 > 32 0.064 4
D1(1) > 256 > 256 1.5 0.5 2 0.032 0.064 3
64(1) A3(1) > 256 12 3 0.5 1.5 > 32 0.125 4
ALL > 256/ 91.7/6e 1.43/ 0.43/ 1.69/ 45.2/0.032e 0.14/ 3.34/
(continued on next page)
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752 S.-C. Lee et al.analysis of the seven housekeeping genes amplified.18e20
Methods of MLST and primers for polymerase chain reac-
tion (PCR) were based on published literature.19,20 We also
typed all VRE isolates with pulsed-field gel electrophoresis
(PFGE).21e24 Genomic DNA was digested with SmaI and
subjected to PFGE. We used the criteria for analysis of
genomic DNA previously described.23,24 Isolates were
judged to be distinct when their pulsed-field gel electro-
phoresis profiles differed by more than three bands.24 For
an additional epidemiological marker, we investigated the
presence of vanA, vanB, vanC1, or vanC2 genes by PCR.
Primers for PCR were based on published gene sequences
for Enterococcus faecalis, Enterococcus faecium, and
Enterococcus gallinarum.15,16
Antibiotics susceptibility
Antimicrobial susceptibility was evaluated by Etest ac-
cording to the guidelines of the Clinical and Laboratory
Standards Institute.17 Minimal inhibitory concentrations
(MICs) of the eight antimicrobial agents, including dapto-
mycin (Cubist Pharmaceuticals, Lexington, MA, USA), fusi-
dic acid (Leo, London, UK), linezolid (Pfizer, New York City,
USA), mupirocin (GlaxoSmithKline, Brentford, London, UK),
teicoplanin (Sanofi-Aventis, Gentilly, France), tigecycline
(Pfizer) trimethoprim/sulfamethoxazole (Sandoz, Geneva,
Switzerland), and vancomycin (Eli Lilly, Indianapolis, Indi-
ana, USA) for the VRE isolates were determined by Etest
(AB Biodisk, Solna, Sweden). The tested antibiotics and
their concentration ranges were: daptomycin
(0.002e32 mg/mL), fusidic acid (0.016e256 mg/mL), line-
zolid (0.016e256 mg/mL), mupirocin (0.064e1024 mg/mL),
teicoplanin (0.016e256 mg/mL), tigecycline (0.016e256 mg/
mL), trimethoprim/sulfamethoxazole (0.002e32 mg/mL),
and vancomycin (0.016e256 mg/mL). The MIC breakpoints
of susceptibility of the five among these eight antimicrobial
agents were: daptomycin ( 4 mg/mL), linezolid (2 mg/
mL), teicoplanin ( 8 mg/mL), tigecycline ( 2 mg/mL,
proposed breakpoint from the FDA), and vancomycin (
4 mg/mL) for VRE according to CLSI M100-S22.17 There were
no approved MIC breakpoints of fusidic acid, mupirocin, and
trimethoprim/sulfamethoxazole for VRE. In Staphylococcus
aureus, the MIC breakpoints of susceptibility for fusidic
acid, mupirocin, and trimethoprim/sulfamethoxazole were
 0.5 mg/mL,  2 mg/mL, and 2/38 mg/mL respec-
tively.25,26 S. aureus MIC breakpoints of susceptibility for
fusidic acid, mupirocin, and trimethoprim/sulfamethoxa-
zole were used for VRE in this study. The following organism
with acceptable MICs (mg/mL) limits were included as
control strains according to CLSI M100-S22 published in
January 2012: Enterococcus faecalis ATCC 29212 (1e4 for
daptomycin, 1e4 for linezolid, 0.125e0.5 for teicoplanin,
0.03e0.12 for tigecycline, and 1e4 for vancomycin).
Results
Between March 1, 2012 and September 30, 2013, there
were 710 critical inpatients admitted to medical ICU and
248 of these 710 inpatients that fit the inclusion criteria
were included in this study. A total of 462 critical inpatients
were excluded from this study due to acute myocardial
Identification of subclinical transmission of VRE in ICU 753ischemia, acute myocardial infarction, and because they
were unwilling to accept rectal swab culture. As shown in
Table 1 for surveillance purpose, 405 rectal swabs were
collected and cultured from these 248 inpatients on and
after admission to our MICU. A total of 66 of these 405
rectal swab cultures were positive for VRE in 46 inpatients
on and after admission to ICU. Of these 66 VRE isolates, six
were duplicate isolates (identical VRE strain, MLST, and
PFGE subtypes from the same inpatient; Table 1). After
removing six duplicate clinical isolates, basic data of 60
nonduplicate VRE isolates are shown in Table 1. The
epidemiological link of VRE in inpatients on and after
admission to ICU are shown in Figure 1. All VRE isolates
carried the vanA gene (45 E. gallinarum, 13 E. faecium, and
2 E. casseliflavus isolates). Of the 45 E. gallinarum isolates,
34 were type ST 341, seven were ST 252, two were ST 78,
and two were ST 64 (Tables 1 and 3). The PFGE subtypes of
these E. gallinarum are shown in Table 1 and Figure 2. Of
the 13 E. faecium isolates, 10 were ST 341, two were ST
252, and one was ST 64. The PFGE subtypes of these E.
faecium isolates are shown in Table 1 and Figure 2. The two
E. casseliflavus isolates belonged to ST 341 (Table 1). Seven
ICU inpatients acquired more than one VRE strainson
admission to ICU and five inpatients acquired more than one
VRE strain after admission to ICU. Although identical VRE
strains with the same MLST were repeatedly isolated from
the same ICU inpatients, their PFGE subtypes were some-
times different.Figure 1. Vancomycin-resistant Enterococcus (VRE) colonization
Taiwan, 2012e2013.A total of 405 rectal swab surveillance cultures were
collected and cultured from 248 inpatients on admission to
ICU (Table 2). A group of 27 of these 248 inpatients (10.9%)
were culture-positive for VRE on admission to ICU (Table 2).
There were 37 VRE isolates obtained from these 27 in-
patients on and after admission to ICU (Table 2). All carried
the vanA gene (28 E. gallinarum and 6 E. faecium). Of these
28 E. gallinarum isolates, 22 were type ST 341, five were ST
252 and one was ST 64 (Table 2). The PFGE subtypes of E.
gallinarum isolates are shown in Table 2. Of the six E.
faecium isolates obtained on admission, five were ST 341
and one was ST 252 (Table 2). The PFGE subtypes of E.
faecium isolates are shown in Table 2. Among the 248 in-
patients admitted to ICU, 221 patients were culture-
negative for VRE on admission to ICU. Of these 221 in-
patients that were culture-negative for VRE on admission to
ICU, follow-up surveillance rectal swab cultures once every
week were performed and 19 converted to culture-positive
for VRE at least once after admission to ICU. The shortest
interval from VRE culture-negative to VRE culture-positive
was 6 days, the longest interval was 22 days, and the
mean was 10.6 days. There were 26 VRE isolates obtained
from these 19 inpatients after admission to ICU. All carried
the vanA gene (17 E. gallinarum, 7 E. faecium, and 2 E.
casseliflavus isolates). Of these 17 E. gallinarum isolates,
12 were type ST 341, two ST 252, two ST 78, and one ST 64
(Table 2). The PFGE subtypes of these E. gallinarum iso-
lates are shown in Table 2. Of these seven E. faeciumin the intensive care unit (ICU) of Keelung Chang Gung Hospital,
Table 2 Comparison of basic data of VRE surveillance cultures isolates, molecular types, and antibiotic susceptibility from MICU patients on and after admission to MICU
excluding six duplicate isolates.a
On admission to MICU
Total patients no.
/positive patients no.
VRE spp (n). vanA
gene
MLST
type (N)
PFGE (N) MIC ug/mL (mean/range)
Fusi Mup Line Tige Dapt
248/27 b Enterococcus
gallinarum (28)
(þ) 341(22) A4(8) 1.84/0.25e3 0.41/0.19e1 0.56/0.19e1 0.65/0.125
e0.94
1.48/0.38
e3
A3(6) 1.81/0.125e3 0.4/0.125
e0.75
0.74/<0.016
e2
0.38/0.064
e0.94
2.04/0.75
e3
B1(1) 2 0.75 1 0.47 0.94
C3(4) 0.5/0.25
e0.75
0.56/0.5e0.75 2/1.5e3 0.58/0.094e2 4/2e6
C1(1) 2 0.38 2 0.064 3
D1(2) 0.5 0.44/0.38e0.5 1.75/1.5e2 0.1/0.094
e0.125
3.5/3e4
252(5) A1(1) 3 0.5 2 0.064 3
A3(1) 2 32 1 0.64 4
D1(1) 0.38 0.75 3 0.064 3
D2(1) 0.75 0.5 1.5 0.125 4
D3(1) 3 0.5 1.5 0.094 3
64(1) A3(1) 0.25 0.75 0.75 6 2
Enterococcus
faecium (6)
(þ) 341(5) A4(1) 1.5 0.125 0.19 0.125 0.38
C3(2) 0.44/0.38
e0.5
0.44/0.38e0.5 1.75/1.5e2 0.16/0.064
e0.25
3
C2(1) 2 0.38 1.5 0.064 3
D1(1) 2 0.38 2 0.094 4
252(1) D1(1) 1.5 0.5 2 0.064 3
Patients culture-negative on admission
Total patients No. c
/þ patients No.d
VRE spp (n). vanA
gene
MLST
type (N)
PFGE
(N)
MIC ug/mL (mean/range)
Fusi Mup Line Tige Dapt
221/19e Enterococcus
gallinarum (17)
(þ) 341(12) A3(4) 2.5/1e3 0.47/0.5
e0.38
1.22/0.38e2 0.25/0.064e0.64 2.5/1e3
A4(2) 2.5/2e3 0.5 1/0.5e1.5 0.55/0.47e0.64 15/6e24
B1(2) 3 0.5 0.75 0.47 3
C3(1) 3 0.5 1 0.094 2
D1(3) 0.5/0.25
e0.75
0.5 2 0.11/0.094
e0.125
4
78(2) A4(2) 3 0.69/0.38e1 256.5/1
e>256
0.94 1.47/0.94
e2
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was ST 64 (Table 2). The two E. casseliflavus isolates
belonged to ST 341 (Table 2). Those inpatients that were
VRE() on admission to ICU and converted to VRE(þ) after
admission to ICU were closed to those inpatients that were
VRE(þ) on admission to ICU at the same time and mostly
were cared for by the same nurses (Figure 1).
Between March 1, 2012 and September 30, 2013, there
were seven clinically overt infections in seven inpatients
caused by seven VRE isolates of which two were bacteremia
and five were symptomatic urinary tract infections. Of
these seven cases with VRE infection, four VRE infections
were likely present on admission to ICU and the remaining
three VRE infections were more likely acquired in the ICU
because these three VRE were isolated > 48 hours after
admission to ICU (Table 4). One of the two blood VRE iso-
lates belonged to E. faecalis ST 414 and the other, E. fae-
cium ST 341 which was catheter-related. Both of the two
bacteremia cases due to VRE were treated with daptomycin
that were active in vitro against VRE but ultimately died of
sepsis despite intensive treatment. Of the other five clinical
VRE isolates, three were E. gallinarum ST 341 and two were
E. faecium ST 341. These five urinary tract infections
caused by VRE were not treated with any VRE-active anti-
biotic such as daptomycin or linezolid but two cases expired
due to other causes and the other three cases remained
stable.
There were 22 single rooms at the MICU of this study. We
performed the environmental cultures of these rooms seven
times, including surface of bedrails, ventilator monitor,
ventilator tubing, EKG monitor, emergency button, inside
room desk surface, and interroom nurse desk surface.
Environmental cultures for VRE were positive on two sur-
faces. One VRE isolate, E. gallinarum, belonging to ST 341
was isolated from the surface of a nurse desk situated be-
tween two rooms. One methicillin-resistant S. aureus
isolate (MLST 239, SCCmec II) was also obtained from this
site. Another VRE isolate belonging to ST 341 was isolated
from the desk surface inside a single room in the MICU.
Of the 45 E. gallinarum, 13 E. faecium, and two E. cas-
seliflavus isolates, all the MICs of vancomycin were over >
256 ug/mL. The range/mean of MICs and susceptibility rate
of teicoplanin, fusidic acid, mupirocin, linezolid, trimetho-
prim/sulfamethoxazole, tigecycline, and daptomycin of
these 60 VRE isolates are described in Tables 1 and 2.Discussion
From our prior study, there was a close relationship be-
tween VRE colonization and VRE symptomatic infections;
similar ST types (414, 78, 18, and 341) and PFGE types (A, C,
D, and E) were identified in patients both asymptomatic for
and clinically manifested VRE.6 This prior study indicated
that infection control policies for VRE would not be suc-
cessful when it included clinically manifested VRE in-
fections while excluding asymptomatic VRE colonization.
Moreover, if the infection control policy could include
asymptomatic VRE colonization, an active VRE surveillance
would then be required.
This current study evaluated the VRE colonization rate,
sequence types, and the route of transmission of VRE to
Table 3 Multilocus sequence types of 66 vancomycin-
resistant Enterococcus isolates.
Serial
No.
Strain ST
a
Assigned No. for allele
AtpA Ddl Gdh PurK Gyd PstS Adk
1 1051 341 15 5 1 1 1 1 1
2 1053 341 15 5 1 1 1 1 1
3 1055 341 15 5 1 1 1 1 1
4 1057 341 15 5 1 1 1 1 1
5 1059 341 15 5 1 1 1 1 1
6 1060 341 15 5 1 1 1 1 1
7 1062 341 15 5 1 1 1 1 1
8 1063 341 15 5 1 1 1 1 1
9 1068 78 15 1 1 1 1 1 1
10 1069 78 15 1 1 1 1 1 1
11 1071 341 15 5 1 1 1 1 1
12 1073 341 15 5 1 1 1 1 1
13 1075 341 15 5 1 1 1 1 1
14 1077 341 15 5 1 1 1 1 1
15 1082 341 15 5 1 1 1 1 1
16 1083 341 15 5 1 1 1 1 1
17 1084 341 15 5 1 1 1 1 1
18 1086 341 15 5 1 1 1 1 1
19 1089 341 15 5 1 1 1 1 1
20 1090 252 1 5 1 1 1 1 1
21 1092 341 15 5 1 1 1 1 1
22 1093 341 15 5 1 1 1 1 1
23 1095 341 15 5 1 1 1 1 1
24 1096 341 15 5 1 1 1 1 1
25 1097 341 15 5 1 1 1 1 1
26 1103 341 15 5 1 1 1 1 1
27 1117 252 1 5 1 1 1 1 1
28 1118 64 7 1 1 1 1 1 1
29 1121 341 15 5 1 1 1 1 1
30 1122 341 15 5 1 1 1 1 1
31 1124 341 15 5 1 1 1 1 1
32 1130 341 15 5 1 1 1 1 1
33 2004 341 15 5 1 1 1 1 1
34 2005 341 15 5 1 1 1 1 1
35 2011 252 1 5 1 1 1 1 1
36 2015 341 15 5 1 1 1 1 1
37 2017 252 1 5 1 1 1 1 1
38 2019 252 1 5 1 1 1 1 1
39 2020 341 15 5 1 1 1 1 1
40 2021 341 15 5 1 1 1 1 1
41 2022 341 15 5 1 1 1 1 1
42 2023 341 15 5 1 1 1 1 1
43 2024 341 15 5 1 1 1 1 1
44 2025 341 15 5 1 1 1 1 1
45 2026 341 15 5 1 1 1 1 1
46 2027 341 15 5 1 1 1 1 1
47 2028 341 15 5 1 1 1 1 1
48 2029 341 15 5 1 1 1 1 1
39 2031 341 15 5 1 1 1 1 1
50 2032 252 1 5 1 1 1 1 1
51 2034 341 15 5 1 1 1 1 1
52 2035 341 15 5 1 1 1 1 1
53 2036 341 15 5 1 1 1 1 1
54 2037 341 15 5 1 1 1 1 1
55 2038 64 7 1 1 1 1 1 1
Table 3 (continued )
Serial
No.
Strain ST
a
Assigned No. for allele
AtpA Ddl Gdh PurK Gyd PstS Adk
56 2040 341 15 5 1 1 1 1 1
57 2041 252 1 5 1 1 1 1 1
58 2042 64 7 1 1 1 1 1 1
59 2045 341 15 5 1 1 1 1 1
60 2046 252 1 5 1 1 1 1 1
61 2047 341 15 5 1 1 1 1 1
62 2050 341 15 5 1 1 1 1 1
63 2051 252 1 5 1 1 1 1 1
64 2052 341 15 5 1 1 1 1 1
65 2053 341 15 5 1 1 1 1 1
66 2054 341 15 5 1 1 1 1 1
a Web site for VRE MLST analysis: http://efaecium.mlst.net/
sql/singlelocus.asp.
MLST Z multilocus sequence typing; ST Z sequence type;
VRE Z vancomycin-resistant enterococcus.
756 S.-C. Lee et al.prove whether subclinical transmission of VRE occurs in the
medical ICU by active surveillance. Of the 248 critical in-
patients admitted to the ICU, 27 patients (10.9%) were
culture-positive for VRE on admission to ICU (Table 2). A
total 10.9% (27/248) VRE colonization rate among in-
patients on admission to ICU was unexpectedly high. These
VRE isolates from inpatients on admission to ICU might be
acquired during stay in the Internal Medicine general ward
or already existing in the patient’s intestinal tract on
admission to the hospital. VRE positive rates among pa-
tients were different between different general wards and
between different hospitals.6,10,18,19 Although all the rooms
in the ICU were single patient rooms, with one nurse taking
care of only two inpatients in the two rooms, cross trans-
mission of VRE via contaminated environment may still
occur if maximal barrier precautions were not performed in
the ICU with a high VRE colonization rate. Of the 221 crit-
ical inpatients culture-negative for VRE on admission to ICU
in this study, 19 inpatients converted to culture-positive for
VRE after admission to ICU. As the VRE spp., MLST and PFGE
subtypes were almost identical among these two groups of
inpatients except one ST 64 E. faecium and two ST 34 E.
casseliflavus identified after admission to ICU, it was highly
possible that these 19 inpatients culture-negative for VRE
on admission to ICU acquired the VRE via cross transmission
from those inpatients already culture-positive for VRE on
admission to ICU (Table 2). As inpatients VRE culture-
negative on admission to ICU become VRE culture-positive
after admission to ICU were closed to inpatients VRE
culture-positive on admission to ICU at the same time as
shown in Figure 1, we could presume that subclinical
transmission of VRE occurred in the ICU. This hypothesis
was further supported by the discovery of two VRE isolates,
one from an inside-room desk surface and the other from an
interroom nurse desk surface. Both environment VRE iso-
lates were E. gallinarum belonging to ST 341, identical to
those of the inpatients at the ICU (Table 3). The reason why
one ST 64 E. faecium and two ST 34 E. casseliflavus were
not discovered on admission to ICU was not clear. It is
possible that those ICU inpatients that did not meet the
Figure 2. Pulsed-field gel electrophoresis types of 21 isolates from 66 vancomycin resistant Enterococcus isolates.
Table 4 Basic data of seven clinically overt VRE infections in ICU.
No. Age
(y)
Sex
M/
F
Specimen/
isolation
daya
VRE spp. Underlying diseases APACHE
III scoreb
Antibiotics
active to
VREc
Outcome C/E/DOD/
COD
1 56 M B/1 Enterococcus
faecium
Traumatic ICH, hemothorax 25 Daptomycin
 20 d
E/22/septic shock, DIC
2 83 F B/19 Enterococcus
faecalis
CHF, IHD,
CKD, DM
17 Daptomycin
 7 d
E/28/nosocomial
pneumonia, septic
shock
3 77 F U/2 Enterococcus
gallinarum
CVD, CKD, bed-ridden 24 Nil C/24
4 99 F U/1 E. gallinarum Cervical cancer with liver, adrenal
gland, & bone metastasis, after CPR
50 Nil E/2/cardiac arrest
5 87 F U/32 E. gallinarum CHF, pneumoconiosis 14 Nil E/28/nosocomial
pneumonia, septic
shock
6 86 F U/19 E. faecium CVD, CKD, bed-ridden 21 Nil C/21
7 70 F U/1 E. faecium CVD 21 Nil C/6
a Days after admission to ICU when isolation of VRE was performed.
b APACHE (Acute Physiology, Age, Chronic Health Evaluation) III score28 on VRE culture (þ) day.
c Antibiotics active to VRE indicate daptomycin or linezolid.
C Z cured; CHF Z congestive heart failure; CKD Z chronic kidney disease; COD Z cause of death; CPR Z cardiopulmonary resusci-
tation; CVD Z cerebrovascular disease; DIC Z disseminated intravascular coagulation; DM Z diabetes mellitus; DOD Z Days after
admission to ICU of discharge or expiry; E Z expired; F Z female; ICH Z intracerebral hemorrhage; ICU Z intensive care unit;
IHD Z ischemic heart disease; M Z male; U Z urine; VRE Z vancomycin-resistant enterococcus.
Identification of subclinical transmission of VRE in ICU 757inclusion criteria might carry these VRE ST strains on
admission to ICU, causing a leak in active surveillance of
inpatients on admission to ICU. As the VRE spp. and MLST
were similar among inpatients with clinical overt infections
due to VRE and inpatients being colonized by VRE without
overt infection, it is highly possible that the eight in-
patients with clinical overt VRE infections acquired the VRE
via cross transmission from those inpatients already
culture-positive for VRE on admission to ICU (Table 2).
Cross transmission via the contaminated environment
and medical personnel are noted as the most possible route
of transmission of VRE at the ICU in this study. According to
our experience, it is very difficult to isolate VRE from thehands of medical personnel because VRE only stay on the
hands of medical personnel transiently, unlike the envi-
ronment surface on which the VRE can survive for a long
time.13 It is known, VRE are easily washed off the hands of
medical personnel during hand washing especially under
investigation. Moreover, some medical personnel may
refuse to cooperate with hand VRE culture for research
purposes when there is no established outbreak of
healthcare-associated infections. Based on these two rea-
sons, hand culture of medical personnel was not performed
in this study. However, we can still infer from the results of
this study that VRE were transmitted via the contaminated
environment and the hands of medical personnel because
758 S.-C. Lee et al.VR-E. gallinarum MLST 341 that were identical to those VRE
isolated from culture (þ) inpatients on and after admission
to ICU were isolated only from the desk surface where the
nurses touched frequently during daily regular work. VR-
Enterococcus faecium might also exist the ICU environment
and was not discovered because surveillance cultures of
environments for VRE to detect contamination were per-
formed only on certain high risk sites every 2e3 months.
After notification of positive desk surface environment
cultures, these surfaces were disinfected more frequently
every day and subsequent environment cultures of these
desk surfaces became negative. No VRE was isolated from
the surface of medical devices, indicating that it was un-
likely that VRE were transmitted via contaminated medical
devices. In the MICU, medical devices were disinfected
regularly according to approved methods. Although the
culture positive rate of the environment was low, two
among seven kinds of surfaces that were most possibly
contaminated by the hands of patients or medical
personnel were positive.
Cho et al18 in Korea reported VR-E. faecium ST 192, ST
78, ST17, and ST 414 (highest to lowest frequency) in 2011.
Lee et al6 in Taiwan discovered VR-E. faecium ST 18 and ST
414 were the most predominant ST types in bacteremia
caused by VRE between 2009 and 2010.18 Our prior study in
2013 also discovered VR-E. faecium ST 414 and ST 18 were
the two most predominant ST types in our nephrology
ward.6 VR-E. faecium ST 341 and ST 78 were also present in
this prior study but comprised only a minority. However, in
this study, the predominant VRE strain and type are VR-E.
gallinarum ST 341 and ST 252 that had not to our knowledge
been reported in Taiwan. VR-E. gallinarum and VR-E. cas-
seliflavus were not found in the prior study in our hospital.
These data indicated that multiple strains of VRE exist in
our hospital and any strain of VRE can cause an outbreak if
strict infection control policies are not followed and
practiced.
From our antimicrobial susceptibility study of VRE, we
found that all VRE isolates were resistant to teicoplanin
compatible with vanA genotype. There were high resistance
rates of fusidic acid and trimethoprim/sulfamethoxazole in
VRE isolates when MICs breakpoint for S. aureus were used
for VRE (Table 1). All VRE isolates were susceptible to
mupirocin and linezolid which can be used clinically to
treat infections caused by VRE. Although there was resis-
tance to daptomycin in some VRE isolates, the resistant
rate was not high, indicating that daptomycin may be
considered to treat infections caused by VRE. Although
there was no resistance to tigecycline in VRE isolates,
tigecycline is not appropriate for treatment of clinically
overt VRE infections because tigecycline urine concentra-
tion is very low according to prior reports and most VRE
systemic infection involves the urinary tract.27 In this study,
we found some ICU inpatients acquired more than one VRE
strain. Although identical VRE strains with the same MLST
were repeatedly isolated from the same ICU inpatients,
their PFGE subtypes were sometimes different. This phe-
nomenon might be caused by amplification of endogenous
strains after hospitalization and antibiotics usage.
There were some limitations in this study. Inpatients in
medical ICU were very critical and many inpatients’ family
refused to participate in this study. Many inpatients,especially cardiological patients in medical ICU, had
myocardial ischemia; in these patients rectal swabs were
contraindicated, resulting in exclusion from study. These
reasons decreased the number of our patients that fit the
criteria for study. Moreover, medical personnel in the
medical ICU refused to accept hand culture because there
was no proved VRE outbreak in the medical ICU and no
regulation enforcing hand culture without an outbreak.
After this study, active surveillance of every critical
inpatient on admission to ICU were regularly performed
after discussion and decision in our Infection Control
Committee. Strict infection control policy including isola-
tion will be performed immediately whenever any inpatient
is known to be colonized by VRE. We conclude that sub-
clinical transmission of VRE occurs in the ICU. If maximal
barrier precautions can prevent cross-transmission of VRE
in the ICU, active surveillance and maximal barrier pre-
cautions for VRE carriers shall be cost-effective in units of
hospitals with high colonization rates of VRE.Conflicts of interest
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